CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful vigilantly but unsuccessfully to produce an one-time therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as being a combination treatment in the healing of multi-drug-resistant HIV happen to be closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. My 1st CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional picture in the Uptick Newswire interview which I came away with a bad opinion of the company.

Irony of irony, the poor opinion of mine of the company has grown steadily, yet the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the therapy as well as reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the expertise and also connected intellectual property from Progenics to CytoDyn, as well as roughly twenty five million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) plus the very first brand new drug program approval ($5 million), and even royalty payments of 5 % of net sales after commercialization.

Since that point in time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and many therapies, it’s this single treatments as well as a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an active company with diverse interests albeit focused on leronlimab, multiple illness sorts, multiple presentations and multiple publications.

Might it all be smoke and mirrors? That is a question I’ve been asking myself from the very start of my interest in this organization. Judging by way of the multiples of a huge number of various responses on listings accessible via Seeking Alpha’s CytoDyn Summary page, I am much from alone in this question.

CytoDyn is a classic battleground, or maybe some may say cult stock. Its adherents are fiercely protective of the prospects of its, quick to label some negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News